-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Contrasting Data Knights Acquisition (NASDAQ:DKDCA) & Bioqual (OTCMKTS:BIOQ)
Contrasting Data Knights Acquisition (NASDAQ:DKDCA) & Bioqual (OTCMKTS:BIOQ)
Data Knights Acquisition (NASDAQ:DKDCA – Get Rating) and Bioqual (OTCMKTS:BIOQ – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.
Institutional & Insider Ownership
97.3% of Data Knights Acquisition shares are owned by institutional investors. 39.2% of Bioqual shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Get Data Knights Acquisition alerts:Analyst Ratings
This is a summary of current ratings and recommmendations for Data Knights Acquisition and Bioqual, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Data Knights Acquisition | 0 | 0 | 0 | 0 | N/A |
Bioqual | 0 | 0 | 0 | 0 | N/A |
Profitability
This table compares Data Knights Acquisition and Bioqual's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Data Knights Acquisition | N/A | N/A | N/A |
Bioqual | 7.92% | 14.90% | 8.53% |
Valuation and Earnings
This table compares Data Knights Acquisition and Bioqual's gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Data Knights Acquisition | N/A | N/A | $5.14 million | N/A | N/A |
Bioqual | $66.15 million | 0.95 | $5.26 million | $5.89 | 11.88 |
Bioqual has higher revenue and earnings than Data Knights Acquisition.
Volatility & Risk
Data Knights Acquisition has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500. Comparatively, Bioqual has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500.
Summary
Bioqual beats Data Knights Acquisition on 6 of the 8 factors compared between the two stocks.
About Data Knights Acquisition
(Get Rating)
Data Knights Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the data centers and internet technology sectors. The company was incorporated in 2021 and is based in Chessington, the United Kingdom.
About Bioqual
(Get Rating)
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Data Knights Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Data Knights Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
Data Knights Acquisition (NASDAQ:DKDCA – Get Rating) and Bioqual (OTCMKTS:BIOQ – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.
数据骑士收购(纳斯达克:DKDCA-GET Rating)和Bioqual(OTCMKTS:BIOQ-GET Rating)都是小盘医疗公司,但哪只是优势股?我们将根据这两家公司的盈利能力、机构所有权、收益、风险、估值、分析师建议和股息等方面的实力进行对比。
Institutional & Insider Ownership
机构与内部人持股
97.3% of Data Knights Acquisition shares are owned by institutional investors. 39.2% of Bioqual shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
97.3%的数据骑士收购股份由机构投资者持有。Bioqual 39.2%的股份由公司内部人士持有。强大的机构持股表明,大型基金管理公司、对冲基金和捐赠基金相信,一家公司的长期表现将好于大盘。
Analyst Ratings
分析师评级
This is a summary of current ratings and recommmendations for Data Knights Acquisition and Bioqual, as reported by MarketBeat.com.
据MarketBeat.com报道,这是对数据骑士收购和Bioqual的当前评级和推荐的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Data Knights Acquisition | 0 | 0 | 0 | 0 | N/A |
Bioqual | 0 | 0 | 0 | 0 | N/A |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
数据骑士收购 | 0 | 0 | 0 | 0 | 不适用 |
Bioqual | 0 | 0 | 0 | 0 | 不适用 |
Profitability
盈利能力
This table compares Data Knights Acquisition and Bioqual's net margins, return on equity and return on assets.
此表比较了Data Knight收购和Bioqual的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Data Knights Acquisition | N/A | N/A | N/A |
Bioqual | 7.92% | 14.90% | 8.53% |
净利润率 | 股本回报率 | 资产回报率 | |
数据骑士收购 | 不适用 | 不适用 | 不适用 |
Bioqual | 7.92% | 14.90% | 8.53% |
Valuation and Earnings
估值和收益
This table compares Data Knights Acquisition and Bioqual's gross revenue, earnings per share (EPS) and valuation.
此表比较了Data Knight的收购和Bioqual的毛收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Data Knights Acquisition | N/A | N/A | $5.14 million | N/A | N/A |
Bioqual | $66.15 million | 0.95 | $5.26 million | $5.89 | 11.88 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
数据骑士收购 | 不适用 | 不适用 | 514万美元 | 不适用 | 不适用 |
Bioqual | 6615万美元 | 0.95 | 526万美元 | $5.89 | 11.88 |
Bioqual has higher revenue and earnings than Data Knights Acquisition.
Bioqual的收入和收益比Data Knight收购的更高。
Volatility & Risk
波动性与风险
Data Knights Acquisition has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500. Comparatively, Bioqual has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500.
数据骑士收购的贝塔系数为-0.01,这意味着其股价的波动性比标准普尔500指数低101%。相比之下,Bioqual的贝塔系数为-0.18,这意味着其股价的波动性比标准普尔500指数低118%。
Summary
摘要
Bioqual beats Data Knights Acquisition on 6 of the 8 factors compared between the two stocks.
在两只股票比较的8个因素中,Bioqual在6个因素上击败了数据骑士收购。
About Data Knights Acquisition
关于数据骑士的收购
(Get Rating)
(获取评级)
Data Knights Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the data centers and internet technology sectors. The company was incorporated in 2021 and is based in Chessington, the United Kingdom.
数据骑士收购公司没有重要的业务。它打算与数据中心和互联网技术领域的一家或多家企业进行合并、资本股票交换、资产收购、股票购买、重组或类似的业务合并。该公司成立于2021年,总部设在英国切辛顿。
About Bioqual
关于Bioqual
(Get Rating)
(获取评级)
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is headquartered in Rockville, Maryland.
Bioqual公司为美国的商业和政府客户提供体内和体外临床前研究服务。该公司提供新冠肺炎、艾滋病、流感、呼吸道合胞病毒感染和黄病毒感染(包括寨卡病毒、登革热、疟疾、肝炎和癌症)等领域的研究服务。它的服务还包括样品处理、病毒库生成、传染性病毒定量、病毒中和试验、血凝抑制试验、定量聚合酶链式反应、抗原和抗体ELISA检测、流式细胞仪、淋巴细胞增殖和其他基于细胞的分析。此外,公司还提供动物研究模型相关服务。Bioqual,Inc.成立于1981年,总部设在马里兰州罗克维尔。
Receive News & Ratings for Data Knights Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Data Knights Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收数据骑士收购的新闻和评级-在下面输入您的电子邮件地址,以通过MarketBeat.com的免费每日电子邮件时事通讯接收对Data Knight收购和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧